Comparative effectiveness of metronidazole and vancomycin for treatment of Clostridioides difficile infection in hospitalized children

被引:0
|
作者
Sandora, Thomas J. [1 ,2 ]
Savage, Timothy J. [1 ,2 ,3 ]
Ryan, Morgan E. [4 ]
Dahlberg, Suzanne E. [2 ,4 ,5 ]
Daugherty, Kaitlyn [2 ,6 ]
Kelly, Ciaran P. [2 ,6 ]
Pollock, Nira R. [2 ,7 ,8 ]
Kociolek, Larry K. [9 ,10 ]
机构
[1] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[4] Boston Childrens Hosp, Biostat Res & Design Ctr, Boston, MA USA
[5] Boston Childrens Hosp, Dept Pediat, Div Pulm Med, Boston, MA USA
[6] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA USA
[8] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA
[9] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Infect Dis, Chicago, IL USA
[10] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
HEALTH-CARE EPIDEMIOLOGY; DISEASES SOCIETY; AMERICA IDSA; GUIDELINES; MANAGEMENT; UPDATE;
D O I
10.1017/ash.2025.51
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare rates of clinical response in children with Clostridioides difficile infection (CDI) treated with metronidazole vs vancomycin.Design: Retrospective cohort study was performed as a secondary analysis of a previously established prospective cohort of hospitalized children with CDI. For 187 participants 2-17 years of age who were treated with metronidazole and/or vancomycin, the primary outcome of clinical response (defined as resolution of diarrhea within 5 days of treatment initiation) was identified retrospectively. Baseline variables associated with the primary outcome were included in a logistic regression propensity score model estimating the likelihood of receiving metronidazole vs vancomycin. Logistic regression using inverse probability of treatment weighting (IPTW) was used to estimate the effect of treatment on clinical response.Results: One hundred seven subjects received metronidazole and 80 subjects received vancomycin as primary treatment. There was no univariable association between treatment group and clinical response; 78.30% (N = 83) of the metronidazole treatment group and 78.75% (N = 63) of the vancomycin group achieved clinical response (P = 0.941). After adjustment using propensity scores with IPTW, the odds of a clinical response for participants who received metronidazole was 0.554 (95% CI: 0.272, 1.131) times the odds of those who received vancomycin (P = 0.105).Conclusions: In this observational cohort study of pediatric inpatients with CDI, the rate of resolution of diarrhea after 5 days of treatment did not differ among children who received metronidazole vs vancomycin.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Vancomycin or metronidazole in the outpatient treatment of mild-moderate Clostridioides difficile infection
    Ross, Patricio
    Oksenberg, Sebastian
    Corsi, Oscar
    Carcamo, Eduardo
    Pereira, Brandon
    Guzman, Ana Maria
    Alvarez, Manuel
    REVISTA CHILENA DE INFECTOLOGIA, 2024, 41 (02): : 193 - 198
  • [2] Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection
    Misawa, Kana
    Iketani, Osamu
    Enoki, Yuki
    Taguchi, Kazuaki
    Uno, Shunsuke
    Uwamino, Yoshifumi
    Hasegawa, Naoki
    Matsumoto, Kazuaki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (10) : 1407 - 1412
  • [3] Changes in Metronidazole and Vancomycin Utilization for Nonsevere Clostridioides difficile Infection Among Institutions Caring for Children
    Stultz, Jeremy S.
    Hopp, Jaclyn
    Orndahl, Christine M.
    Omecene, Nicole E.
    Pakyz, Amy L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (07) : 634 - 636
  • [4] Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
    Dubberke, Erik R.
    Gerding, Dale N.
    Kelly, Ciaran P.
    Garey, Kevin W.
    Rahav, Galia
    Mosley, Audrey
    Tipping, Robert
    Dorr, Mary Beth
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
  • [5] DOES ADDITION OF METRONIDAZOLE TO ORAL VANCOMYCIN IMPROVE OUTCOMES IN CLOSTRIDIOIDES DIFFICILE INFECTION?
    Wang, Ying
    Schluger, Aaron
    Li, Jianhua
    Gomez-Simmonds, Angela
    Freedberg, Daniel E.
    GASTROENTEROLOGY, 2019, 156 (06) : S903 - S903
  • [6] Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection
    Stevens, Vanessa W.
    Nelson, Richard E.
    Schwab-Daugherty, Elyse M.
    Khader, Karim
    Jones, Makoto M.
    Brown, Kevin A.
    Greene, Tom
    Croft, Lindsay D.
    Neuhauser, Melinda
    Glassman, Peter
    Goetz, Matthew Bidwell
    Samore, Matthew H.
    Rubin, Michael A.
    JAMA INTERNAL MEDICINE, 2017, 177 (04) : 546 - 553
  • [7] Vancomycin vs metronidazole use for the treatment of Clostridioides difficile infection in a tertiary care hospital in Saudi Arabia
    Alhameed, Abrar F.
    Saferuddin, Nada
    Alturkistani, Tariq
    Al Musawa, Mohammed
    Damfu, Nader
    Alattas, Majda
    HELIYON, 2023, 9 (11)
  • [8] Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis
    Okumura, Hiroyuki
    Fukushima, Ayako
    Taieb, Vanessa
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (01) : 43 - 50
  • [9] Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang, Ying
    Schluger, Aaron
    Li, Jianhua
    Gomez-Simmonds, Angela
    Salmasian, Hojjat
    Freedberg, Daniel E.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) : 2414 - 2420
  • [10] Vancomycin Versus Metronidazole for Nonsevere Clostridioides difficile Infection: Are the Data Adequate to Change Practice?
    Sarna, Katherine V.
    Gross, Alan E.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 845 - 852